CD8A and neoplasm: A growing body of data from preclinical studies show that multi-target TKIs, especially cabozantinib and lenvatinib, decrease the number of myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAMs), and increase the tumor infiltration of dendritic cells, NK cells, and CD8+ lymphocytes [130].